Price movement over the last 24 hours
ADMA Biologics Inc vs Upwork Inc — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Upwork Inc trades at $8.67 (market cap $1.10B). The key difference: ADMA Biologics Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ADMA | UPWK | |
|---|---|---|
Market Cap | $2.13B | $1.10B |
Sector | Health | Industrials |
52-Week High | $20.38 | $22.11 |
52-Week Low | $7.60 | $7.84 |
Enterprise Value | $2.20B | $895.35M |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
UPWK trades at $8.87, down 3.17% today, with a bullish technical signal from moving averages and ADX indicators. The company reported $787.78M revenue in 2025 with a net income margin of 14.65%, though recent quarters show earnings misses. Positive developments include a new AI partnership with Claude announced June 17, 2026, while legal investigations into securities violations pose headwinds.
The stock presents a mixed outlook: valuation ratios like P/E of 10.94 and EV/EBITDA of 5.8 suggest potential upside to the $10.67 consensus target, but earnings volatility and legal risks require caution. Growth in the gig economy supports long-term opportunity, yet investor sentiment is tempered by recent guidance cuts and shareholder lawsuits.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →